CONMED Corp Q3 FY2026 earnings call

• General Surgery & AirSeal: AirSeal was the primary driver of general surgery growth, fueled by stable disposable sales and strong capital equipment adoption, particularly internationally. The product has received an expanded U.S. clinical indication for use with Intuitive's DaVinci 5 robotic surgical platform, enhancing its marketability. Clinical studies highlight benefits such as shorter procedure times and reduced post-operative pain.
• Smoke Evacuation (Buffalo Filter): Direct smoke evacuation sales grew strongly, while OEM sales declined. The strategic focus remains on direct sales due to higher margins. Legislative tailwinds are accelerating, with new laws enacted in Michigan and Pennsylvania, bringing the total number of states with smoke-free operating room laws to 23, covering approximately 60% of the U.S. population.
• Orthopedic Surgery & BioBrace: BioBrace drove orthopedic growth, supported by international regulatory clearance in Brazil and strong adoption in key markets like Canada, China, and India. The product is clinically differentiated for rotator cuff repairs, with guidelines recommending its use. Domestic U.S. orthopedic sales declined due to ongoing commercial organization restructuring, but growth trends are improving over two and three-year periods.
• Financial Discipline: Adjusted gross margin improved by 40 basis points to 56.4%, and adjusted operating margin increased by 20 basis points to 15.4%. Adjusted EPS of $1.04 exceeded expectations. Free cash flow generation remained robust at $46.4 million.

The company reported net revenue of $335.6 million for the third quarter, representing a 70 basis point decrease on an as-reported basis and an 80 basis point decrease on a constant currency basis. However, organic constant currency sales increased 6.7% year-over-year. General surgery products contributed significantly to this growth, with sales increasing 6.4% on an organic constant currency basis, driven by international markets (15.5% growth) and domestic markets (1.9% growth). Orthopedic surgery products also performed well, with organic constant currency sales increasing 7.2%, primarily due to international growth of 12.7%, which offset a 1.7% decline in domestic sales.

• Full Year 2026 Net Sales: Updated to assume GI revenue of approximately $20 million (down from prior guidance of $20-$22 million) and an FX tailwind of approximately $9 million (up from $7-$7.5 million).
• Organic Constant Currency Growth: Narrowed range to 5.0% - 5.5% (previously 5.0% - 6.0%). Management reaffirmed confidence in achieving at least 5% growth, tightening the high end to reflect a more measured pace of sequential improvement.
• Adjusted Diluted EPS: Increased range to $4.54 - $4.61 (previously $4.48 - $4.60), reflecting better-than-expected Q3 results.
• Fourth Quarter 2026 Guidance: Implies GAAP net sales between $364 million and $370 million (organic constant currency growth of 5.1% - 6.8%) and adjusted EPS between $1.23 and $1.30.
• Key Assumptions: Full-year adjusted gross margin of approximately 57.5%, adjusted interest expense of approximately $33.7 million, and adjusted effective tax rate of approximately 24.5%.

• Debt Refinancing Impact: Increased adjusted interest expense ($10.5 million in Q3 vs. $6.3 million in prior year) due to recent debt refinancing activities, including the repurchase of convertible notes.
• Domestic Commercial Execution: U.S. orthopedic sales continue to face headwinds from structural changes to the commercial organization, though trends are showing signs of improvement.
• OEM Business Volatility: Decline in OEM Buffalo Filter sales highlights the variability associated with indirect supply chains compared to direct-to-customer models.
• Regulatory and Legislative Uncertainty: While legislative tailwinds for smoke evacuation are positive, the evolving landscape requires continuous engagement and adaptation.
• Forward-Looking Statement Risks: Standard risks related to uncertainties that may cause actual results to differ materially from expectations, as detailed in SEC filings.

Q: Why did management narrow the high end of the full-year organic growth guidance from 6% to 5.5%, despite beating Q3 expectations?

A: CFO John Gallagher explained that Q3 performance was boosted by favorable timing of distributor orders internationally, which benefited the quarter but is not expected to repeat in Q4. Consequently, management tightened the range to reflect a more conservative view of the remaining pipeline and to align the implied Q4 growth rate (up to 6.8%) with the sustainable pace observed in Q3, ensuring high confidence in hitting the low-end target of 5%.

Q: What is the current status and strategic direction regarding potential M&A or strategic actions?

A: CEO Pat Beyer stated that while there are rumors, the company does not comment on them. He emphasized that ConMed is currently focused on executing its refined multi-year plan within three core markets: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Management is evaluating M&A opportunities that are accretive to revenue growth and profitability, but near-term priorities remain on deleveraging and optimizing existing operations.

Q: How is management addressing the underperformance in the U.S. orthopedic business, and what is the timeline for recovery?

A: Management acknowledged that U.S. orthopedic sales declined due to active restructuring of the commercial organization. CEO Pat Beyer indicated they are in the "middle innings" of this process, having made significant progress in H1 and Q3. The focus is now on operationalizing distributors and training. Management expects to exit 2026 in a position where U.S. growth resumes in H1 2027, citing improving long-term growth trends despite short-term quarter-on-quarter declines.

Q: What are the specific growth drivers and market penetration strategies for AirSeal in laparoscopic surgery?

A: CEO Pat Beyer highlighted that AirSeal is under-penetrated in laparoscopy (6-7% usage) compared to robotic surgery. To address this, the company is targeting specific high-value procedure categories (colorectal, urology, gynecology, bariatrics) where clinical differentiation offers maximal economic impact. They are implementing procedure-specific training for sales teams and leveraging clinical evidence to win share in these targeted segments rather than pursuing broad, low-yield opportunities.

Q: What are the key factors influencing the updated 2026 financial guidance, specifically regarding FX and GI revenues?

A: CFO John Gallagher clarified that the guidance update reflects two main adjustments: an increase in the assumed foreign exchange tailwind from $7-7.5 million to $9 million, and a reduction in expected Gastroenterology (GI) revenue contributions to $20 million from the previous $20-22 million range. Excluding these items, management maintains strong confidence in the underlying organic growth trajectory, particularly the low-end target of 5%.